Determine the necessary mass, volume, or concentration for preparing a solution.
This is a demo store. No orders will be fulfilled.
| SKU | Size | Availability |
Price | Qty |
|---|---|---|---|---|
|
K650480-5mg
|
5mg |
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
|
$380.90
|
|
|
K650480-10mg
|
10mg |
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
|
$620.90
|
|
|
K650480-25mg
|
25mg |
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
|
$1,250.90
|
|
| Specifications & Purity | ≥98% |
|---|---|
| Biochemical and Physiological Mechanisms | KIF18A-IN-6 (Compound 134) is an orally active KIF18A inhibitor with an IC 50 of 0.016 μM against KIF18A microtubule-dependent ATPase activity. |
| Storage Temp | Store at -20°C |
| Shipped In |
Ice chest + Ice pads This product requires cold chain shipping. Ground and other economy services are not available. |
| Product Description |
KIF18A-IN-6 (Compound 134) is an orally active KIF18A inhibitor with an IC 50 of 0.016 μM against KIF18A microtubule-dependent ATPase activity In Vitro KIF18A-IN-6 (Compound 134; 7 days) inhibits JIMT-1, HCC-15 and NIH-OVCAR3 cells viability with IC 50 s of 0.0040, 0.0051 and 0.0051 μM, respectively. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability AssayCell Line: HCC-15, JIMT-1 and NIH-OVCAR3 Concentration: Incubation Time: 7 days Result: Inhibited cell viability with IC 50 s of 0.0040, 0.0051 and 0.0051 μM against JIMT-1, HCC-15 and NIH-OVCAR3 cells, respectively. In Vivo KIF18A-IN-6 (Compound 134; 10-60 mg/kg; p.o.; twice or once a day for 1 month) inhibits HCC15 and OVCAR3 tumor growth in mice . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: SCID Beige mice, HCC15 tumor model Dosage: 10, 30 and 60 mg/kg Administration: PO, twice a day for 1 month Result: Inhibited tumor growth by 61±10%, 89±7% and 94±5% at 10, 30 and 60 mg/kg, respectively. Animal Model: Balb/C nude mice, OVCAR3 tumor model Dosage: 10, 30 and 60 mg/kg Administration: PO, twice or once a day for 1 month Result: Completely inhibited tumor growth (over 100%) over 30 mg/kg. Form:Solid IC50& Target:IC50: 0.016 μM (KIF18A microtubule-dependent ATPase activity) |
| Smiles | O=S(C1=CC(C(N2CC3(CCC4(CC4)CC3)C5=CC(NS(CC)(=O)=O)=CC=C52)=O)=CC=C1)(NC(C)(C)C)=O |
|---|---|
| Molecular Weight | 559.74 |
| Solubility | DMSO : 125 mg/mL (223.32 mM; Need ultrasonic) |
|---|